drugset / Trial / NCT05868876
A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
A Phase Ia/Ib open label，clinical study evaluating the safety, tolerability and preliminary efficacy of AK127 in combination with AK104 in patients with advanced malignant tumors
Timeline
- Start
- 2023-06-29
- Primary completion
- 2025-11
- Completion
- 2026-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | LANCASTOTUG | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | LANCASTOTUG | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | LANCASTOTUG | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | LANCASTOTUG | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | LANCASTOTUG | Monoclonal antibody | 15 mg/kg | Intravenous |